Upside – $GRML +44% (extends the high-volume Greenland critical-minerals momentum rally) – $VKTX +25% (positive VK2735 maintenance data showed strong weight loss and high retention with biweekly and monthly dosing) – $VICR +8.7% (raises Q3 sequential revenue-growth guidance to more than 20% from nearly 10% on V4PD-license royalties) – $ONON +8.0% (sets high-teens constant-currency sales …
Read in context ›Viking Therapeutics Stock (VKTX)
Track Viking Therapeutics stock through TheStreet Pro's latest coverage, including articles, Daily Diary mentions, TheStreet Pro portfolio activity, contributor watchlist signals, and Pro price levels.
VKTX
Viking Therapeutics
healthcare
At close
$35.56
▼ -1.19 (-3.24%)
Sep 25, 4:00 PM ET
After-hours
$35.53
▼ -0.03 (-0.09%)
Sep 25, 7:59 PM ET
Market Cap
$4.15B
P/E Ratio
—
1Y Return
+41.73%
EPS (TTM)
-$4.66
Read the latest TheStreet Pro articles mentioning Viking Therapeutics, including market roundups, portfolio updates, trade ideas, and investing analysis.
Articles
65 articlesDaily Diary Mentions
26 mentionsUpside, Downside Movers Out of Viking Therapeutics I have sold out my VKTX (common and calls) for a small profit. Position: None
Read in context ›The Case for Viking Therapeutics From last Friday: New buy, old friend - Viking Therapeutics (VKTX- $31.11) More on Monday. By Doug Kass Mar 6, 2026 9:45 AM EST --- The quick case for Viking Therapeutics VKTX: * Top-tier efficacy and safety into Phase 3 trials * The company has the same type of molecule as the superior ...
Read in context ›Things I Did Today Here are today's things: * Buy SPY at $670.50 (S&P cash -105 handles) and sold SPY calls (against on rally at -61 handles lower in S&P cash) for a nice profit. * Buy QQQ at $599.90 (S&P cash -105 handles) and sold QQQ calls (against on rally at -61 handles ...
Read in context ›Exploring a New/Old Trade New buy, old friend - Viking Therapeutics VKTX. More on Monday.
Read in context ›